Business Description:
Avita Medical Ltd (AVH) is a medical technology company that develops and distributes regenerative and tissue-engineered products for the treatment of wounds, scars and skin defects. The company's products comprise regenerative medicine products (ReCell Autologous Spray-On-Skin) and respiratory products (Breath-A-Tech and Funhaler Paediatric Incentive Spacer).

Strategy Analysis:
CCE has developed a number of proprietary products that can be used to treat skin disorders. The products use small samples of patient skin to grow new cells in a solution that can be reapplied to speed up the natural healing process. For severe burns this can be a life saving technology to reduce scarring while also providing plastic surgeons with a tool to replace skin. The lead products are CellSpray, a suspension containing cultured skin cells from the patient for use in the treatment of major burns and scars. ReCell a device that enables the collection of healthy skin cells for immediate application on damaged skin such as small burns, areas of pigment loss and scars. CCE has CE mark approval for ReCell and CellSpray. This means that product can now be marketed and sold across Europe. Management is focused on taking its products to the global market and generating substantial sales growth.